You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CARDURA XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cardura Xl, and what generic alternatives are available?

Cardura Xl is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cardura Xl

A generic version of CARDURA XL was approved as doxazosin mesylate by APOTEX on October 18th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CARDURA XL?
  • What are the global sales for CARDURA XL?
  • What is Average Wholesale Price for CARDURA XL?
Drug patent expirations by year for CARDURA XL
Drug Prices for CARDURA XL

See drug prices for CARDURA XL

Drug Sales Revenue Trends for CARDURA XL

See drug sales revenues for CARDURA XL

Recent Clinical Trials for CARDURA XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Texas Health Science Center, HoustonPhase 1
Brown UniversityPhase 2
University of California, Los AngelesPhase 3

See all CARDURA XL clinical trials

Pharmacology for CARDURA XL

US Patents and Regulatory Information for CARDURA XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-001 Feb 22, 2005 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CARDURA XL

See the table below for patents covering CARDURA XL around the world.

Country Patent Number Title Estimated Expiration
Spain 2045400 ⤷  Sign Up
European Patent Office 0334465 Dispositif pour doser un médicament pour la thérapie humaine. (Dosage form for dispensing drug for human therapy.) ⤷  Sign Up
Canada 1315687 FORME GALENIQUE POUR LIBERER UN MEDICAMENT DESTINE AU TRAITEMENT DES HUMAINS (DOSAGE FORM FOR DISPENSING DRUG FOR HUMAN THERAPY) ⤷  Sign Up
Germany 68910159 ⤷  Sign Up
Mexico 9203554 UN DISPOSITIVO OSMOTICO PARA ADMINISTRAR DOXAZOSIN ⤷  Sign Up
Ireland 890142 ⤷  Sign Up
Austria 96308 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.